Modesto, Anouchka http://orcid.org/0000-0003-2133-6454
Tougeron, David
Tremolières, Pierre
Ronchin, Philippe
Jouve, Ariane Darut
Leignel, Delphine Argo
Vendrely, Véronique
Riou, Olivier
Martin-Babau, Jérôme
Le Sourd, Samuel
Mirabel, Xavier
Leroy, Thomas
Huguet, Florence
Montaigne, Lucile
Baumgaertner, Isabelle
Deslandres, Marion
Moyal, Elizabeth
Seva, Catherine
Selves, Janick
Otal, Philippe
Pezzella, Veronica
Guimbaud, Rosine
Filleron, Thomas
Quéro, Laurent
Funding for this research was provided by:
AstraZeneca France
Article History
Received: 25 October 2022
Accepted: 25 July 2023
First Online: 12 October 2023
Declarations
:
: This trial was reviewed and approved by the French ethics committee CPP EST I Dijon on 5<sup>th</sup> December 2018 according to the Declaration of Helsinki.Registration numbers:EudraCT 2018–000708-40.CPP EST 1: 2018/78.Written consent is obtained for each recruited patients. Unicancer will prepare a lay summary to be distributed to trial participants upon completion of the research.
: This article is not eligible regarding consent of publication.
: AM reports for consulting or advisory role: Merk Serono, Bristol-Myer Squibb, MSD, for research funding: Astra Zeneca (institutional) and for travel grants: Bristol-Myer Squibb, Merk Serono. The rest all authors declare no competing interests related to this study.